ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
15
views
0
references
Top references
cited by
47
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,669
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Current approaches and future directions in the treatment of HER2-positive breast cancer
Author(s):
Sara A Hurvitz
,
Yufang Hu
,
Neil S. O’Brien
,
Richard Finn
Publication date:
2013-05-01
Journal:
Cancer treatment reviews
Publisher:
Elsevier BV
Read this article at
ScienceOpen
Publisher
Further versions
oa repository (via OAI-PMH doi match)
oa repository (via pmcid lookup)
Powered by
Review
Review article
Invite someone to review
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Alternative approaches to Alzheimer's Disease
Author and article information
Journal
DOI::
10.1016/j.ctrv.2012.04.008
License:
https://www.elsevier.com/tdm/userlicense/1.0/
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
1,669
Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial
Authors:
Arlene Chan
,
Beverly Moy
,
Janine Mansi
…
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
Authors:
G Villacampa
,
N M Tung
,
S Pernas
…
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Authors:
S Loibl
,
C Jackisch
,
A Schneeweiss
…
See all similar
Cited by
44
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives
Authors:
Pei Ong
,
Louis Wang
,
Xiaoyun Dai
…
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.
Authors:
A. Labrijn
,
J. Meesters
,
B. E. C. G. de Goeij
…
SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer
Authors:
Jisheng Bao
,
Liping Zhu
,
Meng-Qi Zhu
…
See all cited by
Version 1
- Current
Version 1